150 related articles for article (PubMed ID: 6182005)
1. Human pharmacokinetics of long term 5-hydroxytryptophan combined with decarboxylase inhibitors.
Magnussen I; Van Woert MH
Eur J Clin Pharmacol; 1982; 23(1):81-6. PubMed ID: 6182005
[TBL] [Abstract][Full Text] [Related]
2. The effects of aromatic amino acid decarboxylase inhibitors on plasma concentrations of 5-hydroxytryptophan in man.
Magnussen I; Engbaek F
Acta Pharmacol Toxicol (Copenh); 1978 Jul; 43(1):36-42. PubMed ID: 309271
[TBL] [Abstract][Full Text] [Related]
3. Dose and sex related effects of aromatic aminoacids decarboxylase inhibitors on serum prolactin in humans.
Polleri A; Masturzo P; Murialdo G; Carolei A
Acta Endocrinol (Copenh); 1980 Jan; 93(1):7-12. PubMed ID: 7355667
[TBL] [Abstract][Full Text] [Related]
4. Long-term therapy of myoclonus and other neurologic disorders with L-5-hydroxytryptophan and carbidopa.
Van Woert MH; Rosenbaum D; Howieson J; Bowers MB
N Engl J Med; 1977 Jan; 296(2):70-5. PubMed ID: 401457
[TBL] [Abstract][Full Text] [Related]
5. Plasma accumulation of metabolism of orally administered single dose L-5-hydroxytryptophan in man.
Magnussen I; Jensen TS; Rand JH; Van Woert MH
Acta Pharmacol Toxicol (Copenh); 1981 Sep; 49(3):184-9. PubMed ID: 6175178
[TBL] [Abstract][Full Text] [Related]
6. Intravenous L-5-hydroxytryptophan in normal subjects: an interdisciplinary precursor loading study. Part III: Neuroendocrinological and biochemical changes.
Wirz-Justice A; Pühringer W; Lacoste V; Graw P; Gastpar M
Pharmakopsychiatr Neuropsychopharmakol; 1976 Nov; 9(6):277-88. PubMed ID: 1087733
[TBL] [Abstract][Full Text] [Related]
7. Therapy of intention myoclonus with L-5-hydroxytryptophan and a peripheral decarboxylase inhibitor, MK 486.
Van Woert MH; Sethy VH
Neurology; 1975 Feb; 25(2):135-40. PubMed ID: 1078720
[TBL] [Abstract][Full Text] [Related]
8. [Effect of VB6 on L-DOPA decarboxylase activity in the organs of rats given peripheral L-DOPA decarboxylase inhibitors (author's transl)].
Yoshimine N; Kuzuya F; Mori K; Sakamoto N
Nihon Ronen Igakkai Zasshi; 1978 Nov; 15(6):566-73. PubMed ID: 732010
[No Abstract] [Full Text] [Related]
9. The effect of some decarboxylase inhibitors on striatal tyramines in the mouse.
Juorio AV
Neuropharmacology; 1983 Jan; 22(1):71-3. PubMed ID: 6843786
[TBL] [Abstract][Full Text] [Related]
10. Aterial blood pressure in dogs: effects of m-tyrosine alone or in combination with inhibitors of aromatic amino acid decarboxylase; relative hypotensive potencies of L-dopa, DL-m-tyrosine, and L-m-tyrosine.
Minsker DH; Stokes AL
Experientia; 1974 Sep; 30(9):1051-3. PubMed ID: 4412113
[No Abstract] [Full Text] [Related]
11. Further studies on the effects of 5-hydroxytryptophan on plasma glucose and insulin in the mouse.
Furman BL; Wilson GA
Diabetologia; 1980 Oct; 19(4):386-90. PubMed ID: 7000601
[TBL] [Abstract][Full Text] [Related]
12. Fluoxetine in the treatment of intention myoclonus.
Van Woert MH; Magnussen I; Rosenbaum D; Chung E
Clin Neuropharmacol; 1983 Mar; 6(1):49-54. PubMed ID: 6189599
[TBL] [Abstract][Full Text] [Related]
13. Alterations in brain 5HT and tryptamine content during indoleamine-induced myoclonus in guinea pigs.
Luscombe G; Jenner P; Marsden CD
Biochem Pharmacol; 1983 Jun; 32(12):1857-64. PubMed ID: 6192824
[TBL] [Abstract][Full Text] [Related]
14. The effect of carbidopa and benserazide on human plasma 5-hydroxytryptophan levels.
Young SN; Gauthier S; Chouinard G; Anderson GM; Purdy WC
J Neural Transm; 1982; 53(1):83-7. PubMed ID: 6801200
[TBL] [Abstract][Full Text] [Related]
15. Comparison of L-5-hydroxytryptophan and L-5-hydroxytryptophan inosinate as agents for increasing brain serotonin formation in rats.
Fuller RW; Snoddy HD; Robertson DW
Res Commun Chem Pathol Pharmacol; 1992 Apr; 76(1):121-4. PubMed ID: 1381513
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers.
Da Prada M; Kettler R; Zürcher G; Schaffner R; Haefely WE
Eur Neurol; 1987; 27 Suppl 1():9-20. PubMed ID: 3123242
[TBL] [Abstract][Full Text] [Related]
17. Benserazide decreases central AADC activity, extracellular dopamine levels and levodopa decarboxylation in striatum of the rat.
Jonkers N; Sarre S; Ebinger G; Michotte Y
J Neural Transm (Vienna); 2001; 108(5):559-70. PubMed ID: 11459076
[TBL] [Abstract][Full Text] [Related]
18. Levodopa and decarboxylase inhibitors: a review of their clinical pharmacology and use in the treatment of parkinsonism.
Pinder RM; Brogden RN; Sawyer PR; Speight TM; Avery GS
Drugs; 1976; 11(5):329-77. PubMed ID: 782834
[No Abstract] [Full Text] [Related]
19. Simultaneous determination of 5-hydroxytryptophan and 3-O-methyldopa in dried blood spot by UPLC-MS/MS: A useful tool for the diagnosis of L-amino acid decarboxylase deficiency.
Di Carlo E; Santagata S; Sauro L; Tolve M; Manti F; Leuzzi V; Angeloni A; Carducci C
J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Nov; 1185():122999. PubMed ID: 34715572
[TBL] [Abstract][Full Text] [Related]
20. Caffeine injection raises brain tryptophan level, but does not stimulate the rate of serotonin synthesis in rat brain.
Fernstrom MH; Bazil CW; Fernstrom JD
Life Sci; 1984 Sep; 35(12):1241-7. PubMed ID: 6207403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
